{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T05:12:54Z","timestamp":1790140374717,"version":"4.0.1"},"reference-count":94,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,12,1]],"date-time":"2017-12-01T00:00:00Z","timestamp":1512086400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","croh-online.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1016\/j.critrevonc.2017.09.003","type":"journal-article","created":{"date-parts":[[2017,9,8]],"date-time":"2017-09-08T17:17:06Z","timestamp":1504891026000},"page":"217-226","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"special_numbering":"C","title":["Evaluation and management of skeletal disease in cancer care"],"prefix":"10.1016","volume":"120","author":[{"given":"Anuhya","family":"Kommalapati","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sri Harsha","family":"Tella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary Angelynne","family":"Esquivel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ricardo","family":"Correa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9 (Sep)","key":"10.1016\/j.critrevonc.2017.09.003_bib0005","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1002\/jbmr.2244","article-title":"Low serum thyrotropin level and duration of suppression as a predictor of major osteoporotic fractures-the OPENTHYRO register cohort","volume":"29","author":"Abrahamsen","year":"2014","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.critrevonc.2017.09.003_bib0010","doi-asserted-by":"crossref","first-page":"3","DOI":"10.4161\/cbt.7.1.5163","article-title":"Biology of breast cancer bone metastasis","volume":"7","author":"Akhtari","year":"2008","journal-title":"Cancer Biol. Ther."},{"key":"10.1016\/j.critrevonc.2017.09.003_bib0015","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1159\/000090956","article-title":"Prostate cancer, osteoporosis and fracture risk","volume":"52","author":"Allain","year":"2006","journal-title":"Gerontology"},{"key":"10.1016\/j.critrevonc.2017.09.003_bib0020","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1007\/s00198-007-0439-4","article-title":"Management of cancer treatment-induced bone loss in early breast and prostate cancer\u2014a consensus paper of the Belgian Bone Club","volume":"18","author":"Body","year":"2007","journal-title":"Osteoporos. Int."},{"key":"10.1016\/j.critrevonc.2017.09.003_bib0025","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1093\/annonc\/mdr356","article-title":"High prevalence of vertebral fractures in women with breast cancer starting aromatase inhibitor therapy","volume":"23","author":"Bouvard","year":"2012","journal-title":"Ann. Oncol."},{"issue":"4","key":"10.1016\/j.critrevonc.2017.09.003_bib0030","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1093\/annonc\/mdu008","article-title":"Fracture incidence after 3 years of aromatase inhibitor therapy","volume":"25","author":"Bouvard","year":"2014","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2017.09.003_bib0035","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1038\/leu.2008.174","article-title":"Lenalidomide inhibits osteoclastogenesis, survival factors and bone-remodeling markers in multiple myeloma","volume":"22","author":"Breitkreutz","year":"2008","journal-title":"Leukemia"},{"issue":"7","key":"10.1016\/j.critrevonc.2017.09.003_bib0040","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1200\/JCO.2005.05.3744","article-title":"Zoledronic acid inhibits adjuvant letrozole-induced bone loss in postmenopausal women with early breast cancer","volume":"25","author":"Brufsky","year":"2007","journal-title":"J. Clin. Oncol."},{"issue":"5","key":"10.1016\/j.critrevonc.2017.09.003_bib0045","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1002\/cncr.26313","article-title":"Final 5-year results of Z-FAST trial: adjuvant zoledronic acid maintains bone mass in postmenopausal breast cancer patients receiving letrozole","volume":"118","author":"Brufsky","year":"2012","journal-title":"Cancer"},{"issue":"5","key":"10.1016\/j.critrevonc.2017.09.003_bib0050","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1002\/cncr.23259","article-title":"Effective inhibition of aromatase inhibitor-associated bone loss by zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: ZO-FAST study results","volume":"112","author":"Bundred","year":"2008","journal-title":"Cancer"},{"key":"10.1016\/j.critrevonc.2017.09.003_bib0055","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.morpho.2011.02.004","article-title":"Bone metastasis: histological changes and pathophysiological mechanisms in osteolytic or osteosclerotic localizations. A review","volume":"95","author":"Chappard","year":"2011","journal-title":"Morphologie"},{"key":"10.1016\/j.critrevonc.2017.09.003_bib0060","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1016\/j.ijrobp.2012.11.007","article-title":"Randomized, double-blinded, placebo-controlled, trial of risedronate for the prevention of bone mineral density loss in nonmetastatic prostate cancer patients receiving radiation therapy plus androgen deprivation therapy","volume":"85","author":"Choo","year":"2013","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"10.1016\/j.critrevonc.2017.09.003_bib0065","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1016\/j.ejca.2007.04.022","article-title":"An international field study of the reliability and validity of a disease-specific questionnaire module (the QLQ-MY20) in assessing the quality of life of patients with multiple myeloma","volume":"43","author":"Cocks","year":"2007","journal-title":"Eur. J. Cancer"},{"issue":"2","key":"10.1016\/j.critrevonc.2017.09.003_bib0070","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1093\/annonc\/mds277","article-title":"Zoledronic acid (zoledronate) for postmenopausal women with early breast cancer receiving adjuvant letrozole (ZO-FAST study): Final 60-month results","volume":"24","author":"Coleman","year":"2013","journal-title":"Ann. Oncol."},{"issue":"4 (Oct)","key":"10.1016\/j.critrevonc.2017.09.003_bib0075","first-page":"753","article-title":"Mechanisms of osteolytic and osteoblastic skeletal lesions","volume":"28","author":"David Roodman","year":"2015","journal-title":"Bonekey Rep."},{"issue":"10001","key":"10.1016\/j.critrevonc.2017.09.003_bib0080","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1016\/S0140-6736(15)60908-4","article-title":"Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials","volume":"386","author":"Early Breast Cancer Trialists' Collaborative Group (EBCTCG)","year":"2015","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.critrevonc.2017.09.003_bib0085","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.1093\/annonc\/mdq217","article-title":"Efficacy of zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: 36-month results of the ZO-FAST study","volume":"21","author":"Eidtmann","year":"2010","journal-title":"Ann. Oncol."},{"issue":"30","key":"10.1016\/j.critrevonc.2017.09.003_bib0090","doi-asserted-by":"crossref","first-page":"4875","DOI":"10.1200\/JCO.2008.16.3832","article-title":"Randomized trial of denosumab in patients receiving adjuvant aromatase inhibitors for nonmetastatic breast cancer","volume":"26","author":"Ellis","year":"2008","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2017.09.003_bib0095","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1007\/s10549-009-0352-y","article-title":"Effect of denosumab on bone mineral density in women receiving adjuvant aromatase inhibitors for non-metastatic breast cancer: subgroup analyses of a phase 3 study","volume":"118","author":"Ellis","year":"2009","journal-title":"Breast Cancer Res. Treat."},{"issue":"5","key":"10.1016\/j.critrevonc.2017.09.003_bib0100","doi-asserted-by":"crossref","first-page":"E359","DOI":"10.1002\/ijc.29210","article-title":"Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012","volume":"136","author":"Ferlay","year":"2015","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.critrevonc.2017.09.003_bib0105","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/S0140-6736(10)62344-6","article-title":"Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomized, double-blind study","volume":"377","author":"Fizazi","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.critrevonc.2017.09.003_bib0110","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1177\/1078155208091866","article-title":"Screening and management of osteoporosis in breast cancer patients on aromatase inhibitors","volume":"14","author":"Gibson","year":"2008","journal-title":"J. Oncol. Pharm. Pract."},{"issue":"9","key":"10.1016\/j.critrevonc.2017.09.003_bib0115","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1016\/S1470-2045(08)70204-3","article-title":"Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bone-mineral density substudy","volume":"9","author":"Gnant","year":"2008","journal-title":"Lancet Oncol."},{"issue":"2","key":"10.1016\/j.critrevonc.2017.09.003_bib0120","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1093\/annonc\/mdu544","article-title":"Zoledronic acid combined with adjuvant endocrine therapy of tamoxifen versus anastrozol plus ovarian function suppression in premenopausal early breast cancer: final analysis of the austrian breast and colorectal cancer study group trial 12","volume":"26","author":"Gnant","year":"2015","journal-title":"Ann. Oncol."},{"issue":"9992","key":"10.1016\/j.critrevonc.2017.09.003_bib0125","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/S0140-6736(15)60995-3","article-title":"Adjuvant denosumab in breast cancer (ABCSG-18): a multicentre, randomised, double-blind, placebo-controlled trial","volume":"386","author":"Gnant","year":"2015","journal-title":"Lancet"},{"issue":"5 Suppl","key":"10.1016\/j.critrevonc.2017.09.003_bib0130","doi-asserted-by":"crossref","first-page":"641","DOI":"10.6004\/jnccn.2016.0181","article-title":"NCCN guidelines update: breast cancer","volume":"14","author":"Gradishar","year":"2016","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"10.1016\/j.critrevonc.2017.09.003_bib0135","first-page":"S1","article-title":"NCCN task force report: bone health In cancer care","author":"Gralow","year":"2013","journal-title":"J. Natl. Compr. Cancer Netw."},{"issue":"8861","key":"10.1016\/j.critrevonc.2017.09.003_bib0140","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1016\/0140-6736(93)90756-7","article-title":"Parathyroid hormone-related protein and response to pamidronate in tumour-induced hypercalcemia","volume":"341","author":"Gurney","year":"1993","journal-title":"Lancet"},{"key":"10.1016\/j.critrevonc.2017.09.003_bib0145","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1093\/annonc\/mdn164","article-title":"Practical guidance for the management of aromatase inhibitor-associated bone loss","volume":"19","author":"Hadji","year":"2008","journal-title":"Ann. Oncol."},{"issue":"4","key":"10.1016\/j.critrevonc.2017.09.003_bib0150","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1007\/s00198-013-2615-z","article-title":"Effects of zoledronic acid on bone mineral density in premenopausal women receiving neoadjuvant or adjuvant therapies for HR+ breast cancer: the ProBONE II study","volume":"25","author":"Hadji","year":"2014","journal-title":"Osteoporos. Int."},{"key":"10.1016\/j.critrevonc.2017.09.003_bib0155","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1093\/annonc\/mdv617","article-title":"Adjuvant bisphosphonates in early breast cancer: consensus guidance for clinical practice from a European Panel","author":"Hadji","year":"2016","journal-title":"Ann. Oncol."},{"issue":"7 (Mar)","key":"10.1016\/j.critrevonc.2017.09.003_bib0160","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jbo.2017.03.001","article-title":"Management of aromatase inhibitor-associated bone loss (AIBL) in postmenopausal women with hormone sensitive breast cancer: joint position statement of the IOF, CABS, ECTS, IEG, ESCEO IMS, and SIOG","volume":"23","author":"Hadji","year":"2017","journal-title":"J. Bone Oncol."},{"key":"10.1016\/j.critrevonc.2017.09.003_bib0165","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.critrevonc.2008.07.013","article-title":"Aromatase inhibitor-associated bone loss in breast cancer patients is distinct from postmenopausal osteoporosis","volume":"69","author":"Hadji","year":"2009","journal-title":"Crit. Rev. Oncol. Hematol."},{"issue":"1 (January)","key":"10.1016\/j.critrevonc.2017.09.003_bib0170","first-page":"1","article-title":"American Thyroid Association management guidelines","volume":"26","author":"Haugen","year":"2015","journal-title":"Thyroid"},{"issue":"9 (Mar 20)","key":"10.1016\/j.critrevonc.2017.09.003_bib0175","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1200\/JCO.2010.31.3304","article-title":"Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma","volume":"29","author":"Henry","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2017.09.003_bib0180","doi-asserted-by":"crossref","first-page":"4042","DOI":"10.1200\/JCO.2003.08.017","article-title":"American Society of Clinical Oncologyupdate on the role of bisphosphonates and bone health issues in women with breast cancer","volume":"21","author":"Hillner","year":"2003","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2017.09.003_bib0185","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1001\/jama.2016.19425","article-title":"Effect of longer-interval vs standard dosing of zoledronic acid on skeletal events in patients with bone metastases. a randomized clinical trial","volume":"317","author":"Himelstein","year":"2017","journal-title":"JAMA"},{"issue":"9453","key":"10.1016\/j.critrevonc.2017.09.003_bib0190","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/S0140-6736(04)17666-6","article-title":"Results of the ATAC (arimidex, tamoxifen, alone or in combination) trial after completion of 5 years' adjuvant treatment for breast cancer","volume":"365","author":"Howell","year":"2005","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.critrevonc.2017.09.003_bib0195","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/dju082","article-title":"Magnetic resonance-guided focused ultrasound for patients with painful bone metastases: phase III trial results","volume":"106","author":"Hurwitz","year":"2014","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.critrevonc.2017.09.003_bib0200","series-title":"Dietary Reference Intakes for Calcium and Vitamin D","author":"Institute of Medicine","year":"2011"},{"issue":"10024 (Mar)","key":"10.1016\/j.critrevonc.2017.09.003_bib0205","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/S0140-6736(15)01037-5","article-title":"Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial","volume":"387","author":"James","year":"2016","journal-title":"Lancet"},{"issue":"1 (Feb)","key":"10.1016\/j.critrevonc.2017.09.003_bib0210","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1007\/s10147-016-1037-2","article-title":"A phase III multicenter, randomized, controlled study of combined androgen blockade with versus without zoledronic acid in prostate cancer patients with metastatic bone disease: results of the ZAPCA trial","volume":"22","author":"Kamba","year":"2017","journal-title":"Int. J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2017.09.003_bib0215","doi-asserted-by":"crossref","first-page":"11089","DOI":"10.1158\/0008-5472.CAN-06-2407","article-title":"Preparing the \u2018soil\u2019: the premetastatic niche","volume":"66","author":"Kaplan","year":"2006","journal-title":"Cancer Res."},{"key":"10.1016\/j.critrevonc.2017.09.003_bib0220","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1016\/j.eururo.2012.09.007","volume":"63","author":"Klotz","year":"2013","journal-title":"Eur. Urol."},{"key":"10.1016\/j.critrevonc.2017.09.003_bib0225","doi-asserted-by":"crossref","first-page":"21","DOI":"10.4065\/78.1.21","article-title":"Review of 1027 patients with newly diagnosed multiple myeloma","volume":"78","author":"Kyle","year":"2003","journal-title":"Mayo Clin. Proc."},{"key":"10.1016\/j.critrevonc.2017.09.003_bib0230","doi-asserted-by":"crossref","first-page":"2699","DOI":"10.1182\/blood.V88.7.2699.bloodjournal8872699","article-title":"Activating mutations of N- and K-ras in multiple myeloma show different clinical associations: analysis of the Eastern Cooperative Oncology Group Phase III Trial","volume":"88","author":"Liu","year":"1996","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.critrevonc.2017.09.003_bib0235","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1007\/s00520-015-2915-2","article-title":"Zoledronic acid for treatment of osteopenia and osteoporosis in women with primary breast cancer undergoing adjuvant aromatase inhibitor therapy: a 5-year follow-up","volume":"24","author":"Majithia","year":"2016","journal-title":"Support. Care Cancer"},{"issue":"2","key":"10.1016\/j.critrevonc.2017.09.003_bib0240","doi-asserted-by":"crossref","first-page":"R24","DOI":"10.1186\/bcr2565","article-title":"Management of anastrozole-induced bone loss in breast cancer patients with oral risedronate: results from the ARBI prospective clinical trial","volume":"12","author":"Markopoulos","year":"2010","journal-title":"Breast Cancer Res."},{"key":"10.1016\/j.critrevonc.2017.09.003_bib0245","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1016\/j.biocel.2007.01.022","article-title":"The thalidomide saga","volume":"39","author":"Melchert","year":"2007","journal-title":"Int. J. Biochem. Cell Biol."},{"key":"10.1016\/j.critrevonc.2017.09.003_bib0250","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD003188.pub3","article-title":"Bisphosphonates in multiple myeloma: a network meta-analysis","author":"Mhaskar","year":"2012","journal-title":"Cochrane Database Syst. Rev."},{"issue":"11 (Nov)","key":"10.1016\/j.critrevonc.2017.09.003_bib0255","doi-asserted-by":"crossref","first-page":"483","DOI":"10.4103\/1947-2714.170600","article-title":"Hypercalcemia of malignancy: an update on pathogenesis and management","volume":"7","author":"Mirrakhimov","year":"2015","journal-title":"North Am. J. Med. Sci."},{"key":"10.1016\/j.critrevonc.2017.09.003_bib0260","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1016\/S0140-6736(10)62051-X","article-title":"First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trial","volume":"376","author":"Morgan","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.critrevonc.2017.09.003_bib0265","doi-asserted-by":"crossref","first-page":"5374","DOI":"10.1182\/blood-2011-11-392522","article-title":"Effects of induction and maintenance plus long-term bisphosphonates on bone disease in patients with multiple myeloma: MRC Myeloma IX trial","volume":"119","author":"Morgan","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2017.09.003_bib0270","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1111\/j.1749-6632.1998.tb09914.x","article-title":"Nutrition, osteoporosis, and aging","volume":"854","author":"Nordin","year":"1998","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.critrevonc.2017.09.003_bib0275","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1002\/jbmr.5650110802","article-title":"Estrogen, cytokines, and pathogenesis of postmenopausal osteoporosis","volume":"11","author":"Pacifici","year":"1996","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.critrevonc.2017.09.003_bib0280","first-page":"571","article-title":"The distribution of secondary growths in cancer of the breast","volume":"1","author":"Paget","year":"1989","journal-title":"Lancet"},{"key":"10.1016\/j.critrevonc.2017.09.003_bib0285","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1056\/NEJMoa1213755","article-title":"Alpha emitter radium-223 and survival in metastatic prostate cancer","volume":"369","author":"Parker","year":"2013","journal-title":"N. Engl. J. Med."},{"issue":"7","key":"10.1016\/j.critrevonc.2017.09.003_bib0290","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1016\/S1470-2045(12)70226-7","article-title":"Oral clodronate for adjuvant treatment of operable breast cancer (national surgical adjuvant breast and bowel project protocol B-34): a multicentre, placebo-controlled, randomised trial","volume":"13","author":"Paterson","year":"2012","journal-title":"Lancet Oncol."},{"issue":"5","key":"10.1016\/j.critrevonc.2017.09.003_bib0295","first-page":"1268","article-title":"Parathyroid hormone-related protein and life expectancy in hypercalcemic cancer patients","volume":"78","author":"Pecherstorfer","year":"1994","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"1 (Jan)","key":"10.1016\/j.critrevonc.2017.09.003_bib0300","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1200\/JCO.1996.14.1.78","article-title":"Effect of tamoxifen on bone mineral density measured by dual-energy x-ray absorptiometry in healthy premenopausal and postmenopausal women","volume":"14","author":"Powles","year":"1996","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2017.09.003_bib0305","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2017.35.15_suppl.8005","article-title":"Impact of denosumab (DMB) compared with zoledronic acid (ZA) on renal function in the treatment of myeloma bone disease","volume":"35","author":"Raje","year":"2017","journal-title":"J. Clin. Oncol."},{"issue":"Suppl 1","key":"10.1016\/j.critrevonc.2017.09.003_bib0310","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1016\/j.ctrv.2008.03.007","article-title":"Guidance for the management of breast cancer treatment-induced bone loss: a consensus position statement from a UK Expert Group","volume":"34","author":"Reid","year":"2008","journal-title":"Cancer Treat Rev."},{"key":"10.1016\/j.critrevonc.2017.09.003_bib0315","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1359\/jbmr.1998.13.5.763","article-title":"A unitary model for involutional osteoporosis: estrogen deficiency causes both type I and type II osteoporosis in postmenopausal women and contributes to bone loss in aging men","volume":"13","author":"Riggs","year":"1998","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.critrevonc.2017.09.003_bib0320","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1093\/jnci\/djh141","article-title":"Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer","volume":"96","author":"Saad","year":"2004","journal-title":"J. Natl. Cancer Inst."},{"issue":"8","key":"10.1016\/j.critrevonc.2017.09.003_bib0325","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1054\/bjoc.2001.1729","article-title":"The effect of clodronate and antioestrogens on bone loss associated with oestrogen withdrawal in postmenopausal women with breast cancer","volume":"84","author":"Saarto","year":"2001","journal-title":"Br. J. Cancer"},{"issue":"738","key":"10.1016\/j.critrevonc.2017.09.003_bib0330","article-title":"Effect of radium-223 dichloride on symptomatic skeletal events in patients with castration-resistant prostate cancer and bone metastases: results from a phase 3, double-blind, randomised trial","volume":"15","author":"Sartor","year":"2014","journal-title":"Lancet Oncol."},{"issue":"December 18","key":"10.1016\/j.critrevonc.2017.09.003_bib0335","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1056\/NEJM197512182932502","article-title":"Prostaglandins as mediators of hypercalcemia associated with certain types of cancer","volume":"293","author":"Seyberth","year":"1975","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2017.09.003_bib0340","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1056\/NEJMoa041943","article-title":"Risk of fracture after androgen deprivation for prostate cancer","volume":"352","author":"Shahinian","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2017.09.003_bib0345","doi-asserted-by":"crossref","first-page":"7829","DOI":"10.1073\/pnas.130200197","article-title":"Estrogens suppress RANK ligand induced osteoclast differentiation via a stromal cell independent mechanism involving c-Jun repression","volume":"97","author":"Shevde","year":"2000","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.critrevonc.2017.09.003_bib0350","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1097\/01.ju.0000063820.94994.95","article-title":"Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer","volume":"169","author":"Smith","year":"2003","journal-title":"J. Urol."},{"key":"10.1016\/j.critrevonc.2017.09.003_bib0355","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/S0022-5347(05)00033-9","article-title":"Risk of clinical fracture after gonadotropin-releasing hormone agonist therapy for prostate cancer","volume":"175","author":"Smith","year":"2006","journal-title":"J. Urol."},{"issue":"1 (Jan)","key":"10.1016\/j.critrevonc.2017.09.003_bib0360","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.juro.2007.08.137","article-title":"Toremifene increases bone mineral density in men receiving androgen deprivation therapy for prostate cancer: interim analysis of a multicenter phase 3 clinical study","volume":"179","author":"Smith","year":"2008","journal-title":"J. Urol."},{"key":"10.1016\/j.critrevonc.2017.09.003_bib0365","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S0140-6736(11)61226-9","article-title":"Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomized, placebo-controlled trial","volume":"379","author":"Smith","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.critrevonc.2017.09.003_bib0370","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1200\/JCO.2013.51.6500","article-title":"Randomized controlled trial of early zoledronic acid in men with castration-sensitive prostate cancer and bone metastases: results of CALGB 90202 (alliance)","volume":"32","author":"Smith","year":"2014","journal-title":"J. Clin. Oncol."},{"issue":"19","key":"10.1016\/j.critrevonc.2017.09.003_bib0375","doi-asserted-by":"crossref","first-page":"2735","DOI":"10.1200\/JCO.2011.35.8333","article-title":"Ras inhibition and the survival benefit favoring zoledronic acid compared with denosumab in patients with multiple myeloma","volume":"29","author":"Sorscher","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2017.09.003_bib0380","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1056\/NEJMcp042806","article-title":"Clinical practice. Hypercalcemia associated with cancer","volume":"352","author":"Stewart","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2017.09.003_bib0385","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.jsbmb.2013.09.008","article-title":"Prevention and treatment of postmenopausal osteoporosis","volume":"142","author":"Tella","year":"2014","journal-title":"J. Steroid Biochem. Mol. Biol."},{"key":"10.1016\/j.critrevonc.2017.09.003_bib0390","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1093\/annonc\/mdi235","article-title":"Myeloma bone disease: pathophysiology and management","volume":"16","author":"Terpos","year":"2005","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2017.09.003_bib0395","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.1038\/sj.leu.2403890","article-title":"The combination of intermediate doses of thalidomide with dexamethasone is an effective treatment for patients with refractory\/relapsed multiple myeloma and normalizes abnormal bone remodeling, through the reduction of sRANKL\/osteoprotegerin ratio","volume":"19","author":"Terpos","year":"2005","journal-title":"Leukemia"},{"key":"10.1016\/j.critrevonc.2017.09.003_bib0400","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1111\/j.1365-2141.2006.06356.x","article-title":"Bortezomib reduces serum dickkopf-1 and receptor activator of nuclear factor-kappaB ligand concentrations and normalises indices of bone remodelling in patients with relapsed multiple myeloma","volume":"135","author":"Terpos","year":"2006","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.critrevonc.2017.09.003_bib0405","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1182\/blood-2007-03-067710","article-title":"Myeloma bone disease and proteasome inhibition therapies","volume":"110","author":"Terpos","year":"2007","journal-title":"Blood"},{"issue":"18 (Jun)","key":"10.1016\/j.critrevonc.2017.09.003_bib0410","doi-asserted-by":"crossref","first-page":"2347","DOI":"10.1200\/JCO.2012.47.7901","article-title":"International Myeloma Working Group recommendations for the treatment of multiple myeloma-related bone disease","volume":"31","author":"Terpos","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2017.09.003_bib0415","first-page":"11","article-title":"Pathophysiology and implications of cancer treatment-induced bone loss","volume":"18","author":"Theriault","year":"2004","journal-title":"Oncology (Williston Park)"},{"key":"10.1016\/j.critrevonc.2017.09.003_bib0420","doi-asserted-by":"crossref","first-page":"2483","DOI":"10.1056\/NEJMoa030847","article-title":"The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma","volume":"349","author":"Tian","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2017.09.003_bib0425","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.maturitas.2016.10.007","article-title":"Osteoporosis management in patients with breast cancer: EMAS position statement","volume":"95","author":"Tremollieres","year":"2017","journal-title":"Maturitas"},{"key":"10.1016\/j.critrevonc.2017.09.003_bib0430","doi-asserted-by":"crossref","first-page":"d2238","DOI":"10.1136\/bmj.d2238","article-title":"Levothyroxine dose and risk of fractures in older adults: nested case-control study","volume":"342","author":"Turner","year":"2011","journal-title":"BMJ"},{"key":"10.1016\/j.critrevonc.2017.09.003_bib0435","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1053\/ctrv.2000.0180","article-title":"The effect of chemotherapy on the growing skeleton","volume":"26","author":"van Leeuwen","year":"2000","journal-title":"Cancer Treat. Rev."},{"issue":"6","key":"10.1016\/j.critrevonc.2017.09.003_bib0440","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1200\/JCO.2009.24.5902","article-title":"Prevention of aromatase inhibitor-induced bone loss using risedronate: the SABRE trial","volume":"28","author":"Van Poznak","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2017.09.003_bib0445","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1111\/j.1365-2796.2006.01667.x","article-title":"Fracture risk associated with use of morphine and opiates","volume":"260","author":"Vestergaard","year":"2006","journal-title":"J. Intern. Med."},{"issue":"1","key":"10.1016\/j.critrevonc.2017.09.003_bib0450","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1080\/02841860802167490","article-title":"Fracture risk in patients with different types of cancer","volume":"48","author":"Vestergaard","year":"2009","journal-title":"Acta Oncol."},{"key":"10.1016\/j.critrevonc.2017.09.003_bib0455","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1111\/j.1464-410X.2009.08483.x","article-title":"Long-term changes in bone mineral density and predicted fracture risk in patients receiving androgen-deprivation therapy for prostate cancer, with stratification of treatment based on presenting values","volume":"104","author":"Wadhwa","year":"2009","journal-title":"BJU Int."},{"issue":"6 (Jun)","key":"10.1016\/j.critrevonc.2017.09.003_bib0460","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1210\/jc.2011-3045","article-title":"Osteoporosis in men: an Endocrine Society clinical practice guideline","volume":"97","author":"Watts","year":"2012","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"3","key":"10.1016\/j.critrevonc.2017.09.003_bib0465","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1016\/j.eururo.2014.02.014","article-title":"Prevention of bone metastases in patients with high-risk nonmetastatic prostate cancer treated with zoledronic acid: efficacy and safety results of the Zometa European Study (ZEUS)","volume":"67","author":"Wirth","year":"2015","journal-title":"Eur. Urol. Mar."},{"key":"10.1016\/j.critrevonc.2017.09.003_bib0470","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1111\/j.1365-2141.2005.05733.x","article-title":"Response to bortezomib is associated to osteoblastic activation in patients with multiple myeloma","volume":"131","author":"Zangari","year":"2005","journal-title":"Br. J. Haematol."}],"updated-by":[{"DOI":"10.1016\/j.critrevonc.2018.02.007","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2018,4,1]],"date-time":"2018-04-01T00:00:00Z","timestamp":1522540800000}}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842817302718?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842817302718?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,10,17]],"date-time":"2020-10-17T09:08:50Z","timestamp":1602925730000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842817302718"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,12]]},"references-count":94,"alternative-id":["S1040842817302718"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2017.09.003","relation":{"erratum":[{"id-type":"doi","id":"10.1016\/j.critrevonc.2018.02.007","asserted-by":"object"}]},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2017,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Evaluation and management of skeletal disease in cancer care","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2017.09.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Ireland Ltd.","name":"copyright","label":"Copyright"}]}}